Drug
Osimertinib clinical trials
Also written AZD9291 and Tagrisso.
- studies test it
- 176
- open now
- 45
- in phase 3
- 23
- first study started
- 2013
Keep track of what changes. Save the osimertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
175 studies that test it; most in 2021 (20); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 10 |
| 2015 | 10 |
| 2016 | 14 |
| 2017 | 8 |
| 2018 | 19 |
| 2019 | 13 |
| 2020 | 13 |
| 2021 | 20 |
| 2022 | 20 |
| 2023 | 13 |
| 2024 | 19 |
| 2025 | 8 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 65
- Phase 2
- 106
- Phase 3
- 23
- Phase 4
- 2
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 73 · Other 103
AstraZeneca (40) · National Cancer Institute (NCI) (8) · Memorial Sloan Kettering Cancer Center (5) · Shanghai JMT-Bio Inc. (5) · Sichuan Baili Pharmaceutical Co., Ltd. (4) · Samsung Medical Center (4) · Dana-Farber Cancer Institute (3) · Jonsson Comprehensive Cancer Center (3)
Often tested with
Tested in the same studies.
Pemetrexed (8) · Carboplatin (6) · Cisplatin (5) · Afatinib (4) · Savolitinib (4) · Becotatug (4) · Crizotinib (3) · Palbociclib (3)
Studies
Open first, then newest update. How each study uses osimertinib is read from its arms, and is right about nine times in ten.
Testing it · 176
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeRecruitingPhase 2National Cancer Institute (NCI)NCT03191149Written as Osimertinib
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung CancerRecruitingPhase 1/2Misty ShieldsNCT07153055Written as Osimertinib
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3AbbVieNCT07155187Written as Osimertinib
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingPhase 1/2Genprex, Inc.NCT04486833Written as osimertinib
- Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerRecruitingPhase 1Ohio State University Comprehensive Cancer CenterNCT04780568Written as Osimertinib
- Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07329322Written as Osimertinib
- Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerRecruitingPhase 1Karen Reckamp, MD, MSNCT05401110Written as Osimertinib
- A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07642024Written as Osimertinib
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07535437Written as Osimertinib
- Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerRecruitingPhase 1Nuvectis Pharma, Inc.NCT07315113Written as Osimertinib
- Boosting Osimertinib Blood Brain Barrier PenetrationRecruitingPhase 2Maastricht University Medical CenterNCT07485452Written as Osimertinib & febuxostat
- A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyRecruitingPhase 2Guangdong Association of Clinical TrialsNCT07375316Written as Osimertinib + Sacituzumab Tirumotecan
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingPhase 3Region SkaneNCT06486142Written as Osimertinib
- Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)RecruitingPhase 2Samsung Medical CenterNCT04591002Written as Osimertinib 80 MG
- Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaRecruitingPhase 2Samsung Medical CenterNCT05528458Written as Osimertinib 80Mg Tab
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07323641Written as Osimertinib
- Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyRecruitingPhase 2AstraZenecaNCT07295821Written as Osimertinib
- MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerRecruitingPhase 1Emory UniversityNCT04762199Written as Osimertinib
- A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLCRecruitingPhase 1/2Wayshine Biopharm, Inc.NCT07206498Written as Osimertinib (Tagrisso®)
- A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLCRecruitingPhase 2Shanghai Chest HospitalNCT07058519Written as Osimertinib 80 MG
See all 176 studies that test osimertinib →
Given in every arm · 62 — osimertinib is usual care beside what is tested
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingPhase 3National Cancer Institute (NCI)NCT04181060Written as Osimertinib
- A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver GenesRecruitingPhase 1/2Sichuan Huiyu Pharmaceutical Co., LtdNCT06712680Written as Osimertinib
- Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLCRecruitingPhase 2NYU Langone HealthNCT07874490Written as Osimertinib
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingPhase 3Bristol-Myers SquibbNCT07680790Written as Osimertinib
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3AbbVieNCT07005102Written as Osimertinib (Osi)
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT06618287Written as Osimertinib
- Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04410796Written as Osimertinib
- A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07640789Written as Osimertinib
- Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerRecruitingPhase 3National Taiwan University HospitalNCT07738172Written as Osimertinib
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07622186Written as Osimertinib
- Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 3AstraZenecaNCT06350097Written as Osimertinib
- Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerRecruitingPhase 3NRG OncologyNCT05624996Written as Osimertinib
- Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung CancerRecruitingPhase 1BioNTech SENCT05142189Written as Osimertinib
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerRecruitingPhase 2AkesoNCT07669779Written as Osimertinib
- A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the BrainRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06741085Written as osimertinib
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT05642572Written as Osimertinib
- Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruitingPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT07612137Written as Osimertinib
- Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.Not yet recruitingPhase 2Shanghai Allink Biotherapeutics Co., Ltd.NCT07603791Written as Osimertinib Mesylate Tablets
- A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07376382Written as Osimertinib
- A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06838273Written as Osimertinib
Showing 20 of 62.
As the comparator · 13 — what is tested is compared with osimertinib
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingPhase 1/2Dizal PharmaceuticalsNCT07079475Written as Osimertinib
- TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesRecruitingPhase 2TYK Medicines, IncNCT05948813Written as Osimertinib
- A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06970639Written as Osimertinib Mesylate Tablets
- A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerNot yet recruitingPhase 1/2Beijing Pearl Biotechnology Limited Liability CompanyNCT07285148Written as ANS014004 + Osimertinib
- A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerRecruitingPhase 2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229729Written as Osimertinib Mesylate
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.RecruitingPhase 2Avistone Biotechnology Co., Ltd.NCT06574347Written as Osimertinib
- Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingPhase 2Peking Union Medical College HospitalNCT06752408Written as Osimertinib
- High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesNot yet recruitingPhase 2Taizhou HospitalNCT06319950Written as Osimertinib
- Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)RecruitingPhase 3TYK Medicines, IncNCT05382728Written as Osimertinib
- SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLCNot yet recruitingNot applicableLi ZhangNCT05583409Written as Osimertinib 80 MG
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04487080Written as Osimertinib
- A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active, not recruitingPhase 3AstraZenecaNCT04035486Written as Osimertinib
- Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesStatus unknownPhase 3Shanghai Chest HospitalNCT04870190Written as Osimertinib
Codes
What other systems call osimertinib · ClinicalTrials.gg INT000195
- MeSH (NLM) C000596361osimertinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3C06JJ0Z2OOSIMERTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1721560Confirmed FDA, Wikidata
- Wikidata Q21506464osimertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116377OsimertinibOne source FDA
- DrugBank DB09330One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596361 | osimertinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3C06JJ0Z2O | OSIMERTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1721560 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21506464 | osimertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116377 | Osimertinib | One source FDA |
| DrugBank | DB09330 | — | One source Wikidata |
Also registered as osimertinib mesylate (UNII RDL94R2A16 · RxNorm 1721559).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.